FierceBiotech 4. Juni 2026 Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2
FierceBiotech 4. Juni 2026 As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
FierceBiotech 4. Juni 2026 Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
FierceBiotech 4. Juni 2026 From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
FierceBiotech 4. Juni 2026 Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
FierceBiotech 3. Juni 2026 Lilly, Boehringer to slash at least $1B each from planned investments in Germany
FierceBiotech 3. Juni 2026 As Akeso takes center stage at ASCO, China biotech industry cements its coming of age
FierceBiotech 3. Juni 2026 Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
FierceBiotech 2. Juni 2026 Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo
FierceBiotech 2. Juni 2026 New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
FierceBiotech 2. Juni 2026 ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
FierceBiotech 2. Juni 2026 Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
FierceBiotech 2. Juni 2026 Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks